Soligenix Announces Two-Year Stability Data for ThermoVax Ebolavirus Vaccines
TL;DR
Soligenix's ThermoVax platform gives a strategic edge by enabling stable ebolavirus vaccines without cold-chain, reducing costs and boosting distribution efficiency in pandemic response.
Soligenix's ThermoVax technology stabilizes protein subunit vaccines at up to 40°C for two years, using heat-resistant formulation to maintain potency and simplify storage logistics.
Soligenix's thermostable vaccines improve global health equity by enabling reliable distribution to remote areas, enhancing pandemic preparedness and saving lives in underserved communities.
Soligenix's ebolavirus vaccines achieve 100% protection in primates and remain potent after two years at high temperatures, a breakthrough in vaccine stability science.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has published new data showing extended stability of its ebolavirus vaccines developed with the ThermoVax platform. According to a manuscript accepted by Vaccine, bivalent and trivalent vaccines formulated from Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus antigens retained full potency after two years of storage at temperatures up to 40°C (104°F).
The thermostable vaccines, developed in collaboration with Dr. Axel Lehrer at the University of Hawaiʻi at Mānoa, have demonstrated robust immune responses in animal models, achieving up to 100% protection in non-human primates. This breakthrough addresses one of the most significant challenges in global vaccine distribution—the cold-chain requirement that limits accessibility in resource-limited settings and tropical climates.
Soligenix emphasized that ThermoVax enhances protein subunit vaccines, which are considered the gold standard for safety, by eliminating cold-chain dependencies. This innovation could dramatically improve global vaccine distribution capabilities and enhance pandemic preparedness, particularly for filovirus outbreaks that often occur in regions with limited infrastructure. The technology's ability to maintain vaccine stability under extreme temperature conditions represents a critical advancement for public health initiatives worldwide.
The company's Public Health Solutions business segment, which includes these vaccine programs, has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA). Additional information about Soligenix's developments is available in the company's newsroom at https://ibn.fm/SNGX.
This stability data publication marks a significant milestone in vaccine technology, potentially enabling longer shelf life, reduced storage costs, and improved accessibility to life-saving vaccines in remote and underserved areas. The implications extend beyond ebolavirus protection, as the ThermoVax platform could be applied to other vaccine candidates, including the company's CiVax COVID-19 vaccine candidate, further transforming how vaccines are distributed and administered globally.
Curated from InvestorBrandNetwork (IBN)
